Ask a doctor about a prescription for INYESPRIN 900 MG POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION
Package Leaflet: Information for the Patient
Inyesprin900 mg powder for solution for injection and infusion
lysine acetylsalicylate
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Inyesprin belongs to a group of medicines, salicylic acid derivatives, used to treat pain and fever.
Inyesprin is indicated for:
Do not use this medicine
If you are not sure if you should start taking this medicine, consult your doctor.
Warnings and precautionsConsult your doctor or pharmacist before starting to use Inyesprin:
Interference with diagnostic tests
If you are going to have any diagnostic tests, inform your doctor that you are using Inyesprin, as it may alter the results.
Children and adolescents
This medicine should not be used intravenously in children.
Reye's syndrome is a very rare, potentially fatal disease that has been observed in children and adolescents with signs of viral infection (particularly chickenpox and flu-like episodes) taking acetylsalicylic acid. Consequently, acetylsalicylic acid should only be administered to children and adolescents in this situation following medical advice, when other measures have failed. In case of persistent vomiting, disorders of consciousness, or abnormal behavior, treatment should be interrupted.
In children under 1 month, the administration of acetylsalicylic acid is only justified in certain situations and under medical prescription.
In children, it is recommended to monitor salicylate levels, especially at the start of treatment.
Use in elderly patients
Caution is recommended in elderly patients, especially with renal insufficiency, or those with reduced albumin levels in the blood, as there is a risk of high toxicity.
Other medicines and Inyesprin
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines, including those obtained without a prescription.
Certain medicines may interact with Inyesprin; in these cases, it may be necessary to change the dose or interrupt treatment with one of the medicines.
It is important that you inform your doctor if you are undergoing any of the following treatments:
Using Inyesprin with alcohol
Do not drink alcohol during treatment with Inyesprin, as the use of acetylsalicylic acid in patients who habitually consume alcohol (three or more alcoholic beverages - beer, wine, liquor... - per day) may cause gastric bleeding.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Pregnancy
During the first and second trimester of pregnancy, Inyesprin should not be administered unless it is strictly necessary and the doctor considers it so.
The use of Inyesprin is contraindicated from the 24th week of pregnancy (third trimester).
Breastfeeding
The use of Inyesprin is not recommended during breastfeeding because it is excreted in breast milk.
Driving and using machines
No effects on the ability to drive or use machines have been observed.
Follow exactly the administration instructions of this medicine indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Your doctor will indicate the duration of treatment with Inyesprin.
Administration can be done by deep intramuscular route, direct intravenous route, dissolving the contents of the vial in 5 ml of water for injectables, or in perfusion in neutral solutions.
It is recommended to avoid mixing this medicine with other injectable specialties in the same syringe.
The recommended dose is:
Adults:it is recommended to administer one vial 1 to 3 times a day. Maximum 4 vials/day.
Children:the recommended dose is 20 to 50 mg/kg/day.
This medicine should not be used intravenously in children.
Remember to take your medicine.
If you think the action of this medicine is too strong or too weak, tell your doctor or pharmacist.
If you use more Inyesprin than you should
If you have used more Inyesprin than you should, consult your doctor or pharmacist immediately.
The symptoms of moderate poisoning are: ringing in the ears, hearing disorders, headache, and dizziness.
In case of severe poisoning, the following may appear: fever, increased respiratory rate, metabolic disorders in the blood, coma, cardiovascular collapse, respiratory failure, and a significant decrease in blood sugar levels.
In case of overdose or accidental ingestion, consult the Toxicology Information Service, phone 91 562 04 20. Also, inform your doctor immediately. Bring this leaflet with you.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The frequency of adverse reactions cannot be estimated based on the available data.
Blood and lymphatic system disorders
Hemorrhagic syndromes (nosebleeds, gum bleeding, appearance of purple spots on the skin, etc.) with an increase in bleeding time. The risk of bleeding may persist for 4-8 days after discontinuation of acetylsalicylic acid, which may cause an increased risk of bleeding in case of surgery. Gastrointestinal bleeding and intracranial bleeding may also occur.
Immune system disorders
Hypersensitivity reactions, anaphylactic reactions (generalized allergic reaction, potentially serious), asthma, angioedema (severe allergic reaction with sudden onset of swelling, skin rashes, and difficulty breathing).
Nervous system disorders
Headache, dizziness, hearing loss, ringing in the ears, which are usually indicative of an overdose.
Intracranial bleeding.
Gastrointestinal disorders
Abdominal pain.
Gastrointestinal bleeding, occult or patent (vomiting or stools with blood), which can lead to iron deficiency anemia. The risk of bleeding depends on the dose. Stomach ulcers and perforations.
Hepatobiliary disorders
Elevation of liver enzymes (indicators of liver function), liver damage.
Skin and subcutaneous tissue disorders
Urticaria, skin reactions.
General disorders and administration site conditions
Reye's syndrome (see "Warnings and precautions"), pain, and local skin reactions at the injection site.
If you notice the appearance of:
Stop taking the medicine and consult your doctor immediately, as these may indicate the onset of side effects that require urgent medical attention.
If you experience side effects, consult your doctor or pharmacist, even if it is a side effect not listed in this leaflet.
Reporting of side effects
If you experience any side effects, consult your doctor or pharmacist, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging and on the vial after CAD. The expiration date is the last day of the month indicated.
Do not store above 25°C.
Medicines should not be disposed of via wastewater or household waste. Place the packaging and any unused medicine in the SIGRE collection point at the pharmacy. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Inyesprin Composition
After reconstitution with 5 ml of water for injectables, each ml of the solution contains 180 mg of lysine acetysalicylate.
Product Appearance and Container Content
Inyesprin 900 mg powder for injectable solution is presented in the form of white or light yellow powder in containers containing 100 vials.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Aristo Pharma Iberia, S.L.
C/ Solana, 26
28850, Torrejón de Ardoz
Madrid, Spain
Manufacturer
Medicamentos Internacionales Laboratories, S.A.
C/ Solana, 26
28850, Torrejón de Ardoz
Madrid, Spain
Date of the last revision of this prospectus: September 2021.
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es
--------------------------------------------------------------------------------------------------------------------
This information is intended solely for Healthcare Professionals:
For additional information, please consult the Technical Data Sheet (TDS) of the product
Instructions for Use and Handling
Inyesprin should be prepared for administration by or under the direct supervision of a pharmacist who is familiar with its properties and safe handling requirements.
Preparation of the Inyesprin Solution
Dissolve the contents of the vial extemporaneously in 5 ml of water for injectables. Administration can be done by deep IM, direct IV, or IV perfusion with the help of an excipient (sodium chloride solution, glucose, or sorbitol).
It is recommended to avoid mixing this medication with other injectable specialties in the same syringe.
The disposal of unused medication and all materials that have come into contact with it will be carried out in accordance with local regulations.
For instructions on the administration of Inyesprin, please refer to the TDS.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for INYESPRIN 900 MG POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION – subject to medical assessment and local rules.